TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change From Baseline in Hemoglobin A1c (HbA1c) at Month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of Participants With MRSA Clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Upper Extremity Fugl-Meyer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of a novel behavioral treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Acceptability of a novel behavioral treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Alveolar nitric oxide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: cerebral embolic lesion incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: overall neurocognitive function, change
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: neonatal mortality rates
Endpoint domain: Mortality/survival
Primary endpoint: Lung ventilation assessed by Percentage Ventilation Defect (VD%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Post-operative infection
Endpoint domain: Adverse events/effects
Primary endpoint: Platelet Function Testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Bleeding after IUD placement
Endpoint domain: Adverse events/effects
Primary endpoint: Change in percentage of students considering a career in medicine
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Number of patients with a platelet count greater or equal to 50,000
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Undetectable COVID PCR at Day 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Bone Mineral Density (BMD) of the Total Hip
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VZV infection at one year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Absolute risk difference in non-genetic risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Absolute risk difference in genetic risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Biological safety
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants reporting unsolicited systemic adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Summary of titers of serum vibriocidal antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Overall FLT-PET Bone Marrow Signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall FLT-PET Signal Intensity within Host Secondary Lymphoid Sites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change of Blood oxygen level dependent (BOLD) signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: diagnostic performance of lactoferrin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: diagnostic performance of PCT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: diagnostic performance of Aution® urine dipstick
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the number of deposited particles of inhalation medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change of GERD symptoms (GERD-HRQL)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Antibody levels to SARS CoV-2 Spike protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Fold increase of Spike IgG levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from baseline orofacial esthetic scale (OES) summary score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Time alive and out of hospital
Endpoint domain: Mortality/survival
Primary endpoint: Uptake of behavioral actions
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Number of Patients with Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients with Dose-Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Readiness for hospital discharge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: acute and subacute toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: McCarthy Scales of Children's Abilities (MSCA)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: AUCinf of Eleclazine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCinf of GS-623134
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Eleclazine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of GS-623134
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical pregnancy rate with fetal heart beat
Endpoint domain: Mortality/survival
Primary endpoint: Visual Analogue Scale of Subjective Dry Mouth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dix-Hallpike test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wound seroma requiring aspiration or surgical intervention
Endpoint domain: Adverse events/effects
Primary endpoint: Binary (≥ 50%) restenosis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Oozing and bleeding scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ecchymosis and hematoma formation scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depression Anxiety Stress Scale (DASS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Width of the Cleft Lip
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Columellar Angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nostril Height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nostril Width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in intrahepatic triglyceride content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of incident cervical HPV infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Rate of convulsions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of women reaching Mg therapeutic level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change of oropharyngeal leak pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade of Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Development of any new cancer
Endpoint domain: Mortality/survival
Primary endpoint: Head and Neck Cancer Inventory
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Short treatment of pneumonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Serum HBV DNA values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change in residual platelet aggregation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percent change in platelet reactivity index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Burning pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective satisfaction with treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Subjective satisfaction with treatment results
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Girth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Platelet reactivity units
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in ambulatory blood pressure (BP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cerebrovascular risk assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Renal risk assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percent Reduction in Daily OCS Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearing of fluorescein staining of the central cornea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone Integrity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percentage of Participants with Adverse Events (AEs) or Serious AEs (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants with Anti-Ocrelizumab Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Patients With Complete, Partial, or Minor Response and Without Progressive Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in overall diversity of fecal flora
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in fecal indoles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in fecal iron
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Yale Brown obsessive compulsive scale (Y-BOCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of responders based on CGI rating
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: skeletal muscular function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Extravascular Lung Water Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: C-Reactive Protein Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with DLTs
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in lung function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Survival of the study device
Endpoint domain: Mortality/survival
Primary endpoint: Change in knowledge score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient enrollment in a clinical trial
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Geometric mean concentration (GMC) of IgA antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroconversion factor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of coughing during anesthetic emergence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in stimulated serum C-peptide levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Function score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Peak concentric and eccentric torque of hamstrings and quadriceps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Total sway of the center of pressure (CoP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Bladder Injection Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurological Death
Endpoint domain: Mortality/survival
Primary endpoint: Ipsilateral Stroke
Endpoint domain: Mortality/survival
Primary endpoint: Tumor Volume Reduction Greater Than 25%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percent of urine samples negative for illicit opioids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Presence of vasculogenic mimicry in urothelial carcinomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Mortality (28 day)
Endpoint domain: Mortality/survival
Primary endpoint: Mean SOFA score during ICU LOS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of primary HIV drug associated resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Pharmacokinetic Area under the curve (AUC0-t, AUC0-inf) of Immunoglobulin G (IgG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic Maximum concentration (Cmax) of Immunoglobulin G (IgG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of deep venous thrombosis (DVT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants Who Experienced the Maximum Toxicity Grade (CTCAE Grade ≥ 3)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With at Least One Side Effect, Adverse Event, and Serious Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: IL-6 & D-dimer Score Changes From Baseline to 3 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants Taking Medication as Assigned
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Performance of the novel pathogen detection assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percent Change in UACR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of pulmonary exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Absolute change in percent predicted FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence and cause of deaths
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants in Complete Remission (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative CIN3+
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Composite of Stroke, Systemic Embolism, and Device-related Thrombosis
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of Major Bleeding Events
Endpoint domain: Adverse events/effects
Primary endpoint: LDL cholesterol (LDL-C) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: DEXA Total Fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clamp Derived Insulin Sensitivity (mg/kg/Min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Body fat measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sports Frequency Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: VAS Pain score and Patient Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of myopericarditis following vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: QT Interval Corrected Using Fridericia's Correction (QTcF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area under the concentration-time curve from time 0 to the time of the last observed non-zero concentration (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearance rate of uremic toxins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of subjects with confirmed post-dose positive ADA test result
Endpoint domain: Adverse events/effects
Primary endpoint: Change in the WOMAC Osteoarthritis Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Operating the Soberlink Cellular device
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Grade 3 or greater infusion toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Delayed marrow recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Consonants Correct (PCC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in drug use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Participants With Clinically Relevant Hemolysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Female Participants With Moderate Glucose-6 Phosphate Dehydrogenase (G6PD) Deficiency Experiencing Clinically Relevant Hemolysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Presence of PTSD symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Concentration of IL-8 in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Concentration of NF-Kβ in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Concentration of IL-6 in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Concentration of IL-1β in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Concentration of Nrf2 in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Total Number of AKs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Development Rate of Atherosclerosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Observer Rated Pain Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IRT-derived scores from PROMIS domains
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning
Primary endpoint: IRT-derived scores from PROMIS domains
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: IRT-derived scores from PROMIS domains
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Presence of negative dysphotopsia
Endpoint domain: Adverse events/effects
Primary endpoint: Time to first BPAR episode or treatment failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Hamilton Depression Rating Scale-17 items (HAMD-17)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Functionality of the upper limb
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolic tumour response by PET scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Pathological tumour response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Haemostatic Success at 5 Minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in peripheral blood T cell proliferation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cytokine production in vitro
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Single Leg Stance Test (SLST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Antibody Titers ≥ 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Minimum threshold of enoxaparin's anti-Xa activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in exercise tolerance and functional capacity (peak VO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Aged 6 Months to <9 Years Who Provided Serum Samples for Analysis
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Participants Aged >=65 Years Who Provided Serum Samples for Analysis
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Ongoing pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: change in total and LDL cholesterol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rates of screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reproducibility of the CTP sum score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reproducibility of the pharmacokinetics of NRL972
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants by of Adverse Events Following a Skin Test Procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Experienced a Positive Skin Reaction (Skin Prick Test)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Experienced a Positive Skin Reaction (Intradermal Test in Healthy Volunteers)
Endpoint domain: Adverse events/effects